Press Release: Myqorzo and Redemplo approved in China Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndromeUnderscores Sanofi’s long-term commitment to China, reinforcing the ambition to provide transformative medicines to patients in disease areas with large unmet medical needs Paris, January 15, 2026. The National Medical Products Administration in China has approved two Sanofi-licensed innovative medicines, Myqorzo (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy ...
Communiqué de presse : Myqorzo et Redemplo approuvés en Chine Myqorzo et Redemplo approuvés en Chine Approbation de Myqorzo pour la cardiomyopathie hypertrophique obstructive et de Redemplo pour le syndrome de chylomicronémie familiale.Souligne l’engagement à long terme de Sanofi envers la Chine et renforce son ambition de fournir des médicaments transformateurs aux patients atteints de maladies présentant d’importants besoins médicaux non satisfaits. Paris, le 15 janvier 2026. L’Administration nationale des produits médicaux en Chine a approuvé deux médicaments innovants sous lic...
Sanofi: Information concerning the total number of voting rights and shares - December 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,438,854,192Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry ...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Decembre 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 438 854 192 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris Date Nombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris acti...
Heineken Holding N.V. reports transactions under its current share buyback programme Heineken Holding N.V. reports transactions under its current share buyback programme Amsterdam, 12 January 2026 - Heineken Holding N.V. (EURONEXT:HEIO; OTCQX: HKHHY), hereby reports transaction details related to the first tranche of up to circa €375 million tranche of its share buyback programme of up to circa €750 million as communicated on 12 February 2025. From 5 January 2026 up to and including 9 January 2026 a total of 219,305 shares were repurchased on exchange at an average price of € 61.47. Up...
We hosted our 29th ODDO BHF Forum in Lyon on 8 and 9 January 2026. In total, 220 companies presented over the two days. In the following note, we provide some initial feedback from the companies on Day 2, in addition to Day 1 feedback (Link to Day 1 feedback). Key positive companies were Corbion, DEME, Elia Group, Knorr Bremse, Sulzer, Séché Environnement, Fraport, Vallourec and TUI. More cautious companies were Arkema, Fastned, INWIT, Manitou, Roche Bobois, Téléperformance, and Colonial SFL. T...
Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D patientsTeizeild represents a potential significant change in the treatment of autoimmune T1D, preventing the natural disease progression protecting beta-cell function Paris, January 12, 2026. The European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D)...
Communiqué de presse : Teizeild de Sanofi approuvé dans l'UE pour les patients atteints de diabète de type 1 de stade 2 Teizeild de Sanofi approuvé dans l'UE pour les patients atteints de diabète de type 1 de stade 2 Approbation basée sur l’étude de phase 2 TN-10 qui a démontré un retard significatif dans l’apparition du DT1 de stade 3 chez les patients atteints du DT1 de stade 2Teizeild représente un potentiel changement significatif dans le traitement du DT1 auto-immun en empêchant la progression naturelle de la maladie, en protégeant la fonction des cellules bêta Paris, le 12 janvier 2...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.